Examining Unmet Needs for Patients with Vasomotor Symptoms Due to MENOPAUSE: Challenges with Traditional Therapeutic Options and the Rationale for Novel Treatments
Post-Test/Evaluation

Questions marked with a * are required
22%
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Judy is a 48-year-old woman who has been struggling with vasomotor symptoms, specifically hot flashes and night sweats, for the past 2 years. Her symptoms are likely caused by dysregulation of the thermoregulatory zone by which type of KNDy neuron receptors? 
Which of the following is an FDA-approved nonhormonal drug treatment option for women with vasomotor symptoms (VMS) due to menopause?
Linda is a 51-year-old woman with VMS. As she has a history of venous thrombosis, she is not a viable candidate for oral hormonal therapy. She has also suffered from refractory insomnia unrelated to menopause. As a part of shared decision making, her gynecologist included discussion of clinical trials testing neurokinin receptor agonists in women with VMS due to menopause. Which of the following approaches could potentially address both VMS and insomnia? 
Which of the following is recognized as an effective strategy for effective communication with patients who are considering treatment options for VMS?
Powered by QuestionPro